For example, the STAT3 nucleotide inhibitor AZD9150 has demonstrated some oncogenic effects in lung and lymphoma patients, and BBI608, a STAT3 inhibitor, can inhibit the proliferation of cervical cancer primary cells in patients [50,51]. Here, STAT3 is linked to lymphoma.